BXRX - Baudax Bio, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Malvern,
United States
Type: Equity
BXRX price evolution
BXRX
| (in millions $) | 31 Jan 2023 | 30 Sep 2022 | 30 Jun 2022 | 31 Mar 2022 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $5.65 | $5.21 | $11.53 | |
| Short term investments | ||||
| Net receivables | $0.31 | $0.62 | $0.61 | |
| Inventory | $4.48 | $5.25 | $5.21 | |
| Total current assets | $11.27 | $12.48 | $19.72 | |
| Long term investments | ||||
| Property, plant & equipment | $1.24 | $4.94 | $4.99 | |
| Goodwill & intangible assets | $4.13 | $22.52 | $23.16 | |
| Total noncurrent assets | $6.24 | $28.36 | $29.1 | |
| Total investments | ||||
| Total assets | $17.51 | $40.83 | $48.81 | |
| Current liabilities | ||||
| Accounts payable | $3.61 | $3.06 | $3.28 | |
| Deferred revenue | ||||
| Short long term debt | $5.91 | $3.61 | $3.06 | |
| Total current liabilities | $21.27 | $18.18 | $20.4 | |
| Long term debt | $2.17 | $5.1 | $5.71 | |
| Total noncurrent liabilities | $15.78 | $18.42 | $18.67 | |
| Total debt | $8.09 | $8.71 | $8.76 | |
| Total liabilities | $37.05 | $36.6 | $39.07 | |
| Shareholders' equity | ||||
| Retained earnings | -$181.65 | -$152.43 | -$144.9 | |
| Other shareholder equity | ||||
| Total shareholder equity | -$19.54 | $4.23 | $9.74 | |
| (in millions $) | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $15.89 | $30.34 | $17.74 | |
| Short term investments | ||||
| Net receivables | $0.54 | $0.05 | ||
| Inventory | $5 | $2.98 | ||
| Total current assets | $23.49 | $36.72 | $20.14 | |
| Long term investments | ||||
| Property, plant & equipment | $5.01 | $5.63 | $5.55 | |
| Goodwill & intangible assets | $23.8 | $26.38 | $28.53 | |
| Total noncurrent assets | $29.78 | $32.02 | $34.08 | |
| Total investments | ||||
| Total assets | $53.28 | $68.73 | $54.21 | |
| Current liabilities | ||||
| Accounts payable | $1.47 | $3.65 | $0.27 | |
| Deferred revenue | ||||
| Short long term debt | $2.22 | $1.02 | $0.32 | |
| Total current liabilities | $15.65 | $18.13 | $7.71 | |
| Long term debt | $6.31 | $8.76 | $0.46 | |
| Total noncurrent liabilities | $24.41 | $65.4 | $63.22 | |
| Total debt | $8.53 | $9.78 | $0.77 | |
| Total liabilities | $40.05 | $83.53 | $70.93 | |
| Shareholders' equity | ||||
| Retained earnings | -$132.09 | -$112.32 | -$36.22 | |
| Other shareholder equity | ||||
| Total shareholder equity | $13.23 | -$14.8 | -$16.72 | |
| (in millions $) | 30 Sep 2022 | 30 Jun 2022 | 31 Mar 2022 | 31 Dec 2021 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $0.24 | $0.3 | $0.42 | $0.4 |
| Cost of revenue | $1.21 | $0.36 | $0.65 | $0.58 |
| Gross Profit | -$0.97 | -$0.06 | -$0.23 | -$0.18 |
| Operating activities | ||||
| Research & development | $0.65 | $0.91 | $1.29 | $0.5 |
| Selling, general & administrative | $3.81 | $4.03 | $14.19 | $11.54 |
| Total operating expenses | $26.5 | $5.58 | $16.13 | $12.69 |
| Operating income | -$27.48 | -$5.65 | -$16.35 | -$12.86 |
| Income from continuing operations | ||||
| EBIT | -$29.2 | -$7.53 | -$12.81 | $31.74 |
| Income tax expense | ||||
| Interest expense | $2.3 | |||
| Net income | ||||
| Net income | -$29.2 | -$7.53 | -$12.81 | $29.43 |
| Income (for common shares) | -$29.2 | -$7.53 | -$12.81 | $27.01 |
| (in millions $) | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 | 31 Dec 2018 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $1.08 | $0.49 | ||
| Cost of revenue | $2.44 | $1.73 | ||
| Gross Profit | -$1.36 | -$1.24 | ||
| Operating activities | ||||
| Research & development | $3.13 | $9.09 | $20.06 | $35.58 |
| Selling, general & administrative | $45.31 | $43.34 | $27.01 | $29.45 |
| Total operating expenses | $51.01 | $54.57 | $47.07 | $65.04 |
| Operating income | -$52.38 | -$55.81 | -$47.07 | -$65.04 |
| Income from continuing operations | ||||
| EBIT | -$17.47 | -$74.74 | -$32.56 | -$73.67 |
| Income tax expense | ||||
| Interest expense | $2.3 | $1.36 | ||
| Net income | ||||
| Net income | -$19.77 | -$76.1 | -$32.56 | -$73.67 |
| Income (for common shares) | -$22.19 | -$76.1 | -$32.56 | -$73.67 |
| (in millions $) | 30 Sep 2022 | 30 Jun 2022 | 31 Mar 2022 | 31 Dec 2021 |
|---|---|---|---|---|
| Net income | -$29.2 | -$7.53 | -$12.81 | $29.43 |
| Operating activities | ||||
| Depreciation | $0.68 | $0.69 | $0.69 | $0.69 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $0.31 | $0.34 | $0.52 | $0.66 |
| Total cash flows from operations | -$3.89 | -$7.22 | -$12.9 | -$12.65 |
| Investing activities | ||||
| Capital expenditures | -$0.02 | -$0.13 | ||
| Investments | $10.15 | |||
| Total cash flows from investing | -$0.02 | $10.02 | ||
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $5.36 | $1.68 | $9.06 | $3.74 |
| Net borrowings | -$0.83 | -$0.28 | ||
| Total cash flows from financing | $4.33 | $0.9 | $8.56 | $3.74 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $0.44 | -$6.32 | -$4.36 | $1.12 |
| (in millions $) | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 | 31 Dec 2018 |
|---|---|---|---|---|
| Net income | -$19.77 | -$76.1 | -$32.56 | -$73.67 |
| Operating activities | ||||
| Depreciation | $2.82 | $2.55 | $0.48 | $0.4 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $4.79 | $9.34 | $5.46 | $4.57 |
| Total cash flows from operations | -$49.27 | -$44.06 | -$50.04 | -$59.75 |
| Investing activities | ||||
| Capital expenditures | -$0.2 | -$0.64 | -$1.48 | -$3.45 |
| Investments | $0.01 | |||
| Total cash flows from investing | -$0.19 | -$0.64 | -$1.48 | -$3.45 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $42.88 | $50.82 | ||
| Net borrowings | $10.04 | |||
| Total cash flows from financing | $35.01 | $57.3 | $69.27 | $63.2 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$14.45 | $12.6 | $17.74 | |
News
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | N/A |
| Revenue | $1.36M |
|---|---|
| EBITDA | -$15.06M |
| EBIT | -$17.81M |
| Net Income | -$20.11M |
| Revenue Q/Q | -15.30% |
| Revenue Y/Y | 79.89% |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | N/A |
| Quick ratio | N/A |